vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

Editas Medicine, Inc. is the larger business by last-quarter revenue ($24.7M vs $22.2M, roughly 1.1× FiscalNote Holdings, Inc.). On growth, Editas Medicine, Inc. posted the faster year-over-year revenue change (-19.2% vs -24.7%). FiscalNote Holdings, Inc. produced more free cash flow last quarter ($-1.9M vs $-36.4M). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs -16.8%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

EDIT vs NOTE — Head-to-Head

Bigger by revenue
EDIT
EDIT
1.1× larger
EDIT
$24.7M
$22.2M
NOTE
Growing faster (revenue YoY)
EDIT
EDIT
+5.5% gap
EDIT
-19.2%
-24.7%
NOTE
More free cash flow
NOTE
NOTE
$34.5M more FCF
NOTE
$-1.9M
$-36.4M
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
-16.8%
NOTE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EDIT
EDIT
NOTE
NOTE
Revenue
$24.7M
$22.2M
Net Profit
$-5.6M
Gross Margin
Operating Margin
-31.3%
-83.7%
Net Margin
-22.7%
Revenue YoY
-19.2%
-24.7%
Net Profit YoY
87.6%
EPS (diluted)
$0.03
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
NOTE
NOTE
Q4 25
$24.7M
$22.2M
Q3 25
$7.5M
$22.4M
Q2 25
$3.6M
$23.3M
Q1 25
$4.7M
$27.5M
Q4 24
$30.6M
$29.5M
Q3 24
$61.0K
$29.4M
Q2 24
$513.0K
$29.2M
Q1 24
$1.1M
$32.1M
Net Profit
EDIT
EDIT
NOTE
NOTE
Q4 25
$-5.6M
Q3 25
$-25.1M
$-24.9M
Q2 25
$-53.2M
$-13.3M
Q1 25
$-76.1M
$-4.3M
Q4 24
$-45.4M
Q3 24
$-62.1M
$-14.9M
Q2 24
$-67.6M
$-12.8M
Q1 24
$-62.0M
$50.6M
Operating Margin
EDIT
EDIT
NOTE
NOTE
Q4 25
-31.3%
-83.7%
Q3 25
-325.4%
-43.4%
Q2 25
-1440.6%
-31.9%
Q1 25
-1635.1%
-50.0%
Q4 24
-152.2%
-19.4%
Q3 24
-107649.2%
-23.1%
Q2 24
-14016.2%
-27.2%
Q1 24
-5902.3%
-35.6%
Net Margin
EDIT
EDIT
NOTE
NOTE
Q4 25
-22.7%
Q3 25
-333.0%
-110.8%
Q2 25
-1487.8%
-57.0%
Q1 25
-1633.5%
-15.4%
Q4 24
-148.3%
Q3 24
-101870.5%
-50.7%
Q2 24
-13178.8%
-43.6%
Q1 24
-5458.1%
157.6%
EPS (diluted)
EDIT
EDIT
NOTE
NOTE
Q4 25
$0.03
$-2.81
Q3 25
$-0.28
$-1.73
Q2 25
$-0.63
$-0.08
Q1 25
$-0.92
$-0.03
Q4 24
$-0.55
$1.88
Q3 24
$-0.75
$-1.33
Q2 24
$-0.82
$-0.09
Q1 24
$-0.76
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$146.6M
$26.3M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$27.3M
$62.0M
Total Assets
$186.5M
$255.1M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
NOTE
NOTE
Q4 25
$146.6M
$26.3M
Q3 25
$165.6M
$31.2M
Q2 25
$178.5M
$38.5M
Q1 25
$221.0M
$46.3M
Q4 24
$269.9M
$34.6M
Q3 24
$265.1M
$32.7M
Q2 24
$279.1M
$37.7M
Q1 24
$296.2M
$43.6M
Total Debt
EDIT
EDIT
NOTE
NOTE
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$57.4M
$147.1M
Q3 24
$152.2M
Q2 24
$145.9M
Q1 24
$153.0M
Stockholders' Equity
EDIT
EDIT
NOTE
NOTE
Q4 25
$27.3M
$62.0M
Q3 25
$13.5M
$75.5M
Q2 25
$19.2M
$95.1M
Q1 25
$62.4M
$98.7M
Q4 24
$134.3M
$97.8M
Q3 24
$175.6M
$98.5M
Q2 24
$232.0M
$106.9M
Q1 24
$294.4M
$106.1M
Total Assets
EDIT
EDIT
NOTE
NOTE
Q4 25
$186.5M
$255.1M
Q3 25
$201.8M
$273.9M
Q2 25
$210.6M
$288.3M
Q1 25
$263.7M
$299.7M
Q4 24
$341.6M
$326.2M
Q3 24
$327.6M
$337.9M
Q2 24
$384.8M
$346.3M
Q1 24
$440.3M
$357.8M
Debt / Equity
EDIT
EDIT
NOTE
NOTE
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
0.43×
1.50×
Q3 24
1.54×
Q2 24
1.36×
Q1 24
1.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
NOTE
NOTE
Operating Cash FlowLast quarter
$-36.4M
$-279.0K
Free Cash FlowOCF − Capex
$-36.4M
$-1.9M
FCF MarginFCF / Revenue
-147.3%
-8.7%
Capex IntensityCapex / Revenue
0.2%
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
NOTE
NOTE
Q4 25
$-36.4M
$-279.0K
Q3 25
$-30.8M
$-8.3M
Q2 25
$-50.2M
$-6.2M
Q1 25
$-47.8M
$3.3M
Q4 24
$-50.8M
$-1.3M
Q3 24
$-52.6M
$-3.0M
Q2 24
$-57.1M
$-3.7M
Q1 24
$-49.9M
$2.7M
Free Cash Flow
EDIT
EDIT
NOTE
NOTE
Q4 25
$-36.4M
$-1.9M
Q3 25
$-31.3M
$-10.4M
Q2 25
$-7.7M
Q1 25
$-47.9M
$1.3M
Q4 24
$-51.3M
$-3.4M
Q3 24
$-55.5M
$-5.4M
Q2 24
$-60.6M
$-6.5M
Q1 24
$-51.7M
$1.0M
FCF Margin
EDIT
EDIT
NOTE
NOTE
Q4 25
-147.3%
-8.7%
Q3 25
-414.6%
-46.2%
Q2 25
-33.0%
Q1 25
-1028.6%
4.7%
Q4 24
-167.6%
-11.4%
Q3 24
-90998.4%
-18.4%
Q2 24
-11804.3%
-22.1%
Q1 24
-4558.9%
3.3%
Capex Intensity
EDIT
EDIT
NOTE
NOTE
Q4 25
0.2%
7.4%
Q3 25
5.7%
9.3%
Q2 25
0.0%
6.4%
Q1 25
2.4%
7.2%
Q4 24
1.8%
6.8%
Q3 24
4788.5%
8.3%
Q2 24
681.1%
9.4%
Q1 24
164.8%
5.3%
Cash Conversion
EDIT
EDIT
NOTE
NOTE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EDIT
EDIT

Segment breakdown not available.

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons